CLIMARA PRO (estradiol and levonorgestrel) by Bayer is estrogen receptor agonists [moa]. Approved for estrogen [epc]. First approved in 2003.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CLIMARA PRO is a transdermal estradiol and levonorgestrel combination therapy approved in 2003 for vasomotor symptoms associated with menopause, with off-label use in Type 2 Diabetes and NASH. It works as an estrogen receptor agonist delivered via an extended-release film patch.
Product is in late lifecycle with modest Medicare spending ($4M in 2023); expect lean, maintenance-focused team structure with limited headcount growth.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants
A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants
Worked on CLIMARA PRO at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCLIMARA PRO generates no linked job openings in pharmaceutical career databases, reflecting its maturity and commercial decline. Bayer's investment in this asset is primarily in maintenance and defend-against-generic strategies rather than growth roles.